Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Oct 30;15(4):417-423.
doi: 10.17085/apm.19067.

Dosing study of esmolol for reducing hemodynamic changes during lightwand intubation

Affiliations

Dosing study of esmolol for reducing hemodynamic changes during lightwand intubation

Jin Ku Kang et al. Anesth Pain Med (Seoul). .

Abstract

Background: Lightwand is a convenient tool that can be used instead of a laryngoscope for intubation. Tracheal intubation causes direct stimulation of the larynx, drastically increasing hemodynamic values including blood pressure and heart rate. This study aims to identify the effect of different doses of esmolol on hemodynamic changes during lightwand intubation.

Methods: The study subjects included 140 patients who underwent general anesthesia for elective surgery. The patients were randomly divided into four groups (35 patients in each group). The 'C' group only received 20 ml of normal saline, while the 'E0.5', 'E1', and 'E2' groups received 20 ml of normal saline containing esmolol-0.5 mg/kg, 1 mg/kg, and 2 mg/kg, respectively, injected 2 min prior to intubation. The patients' blood pressure, heart rate, and rate-pressure product were measured six times, before and after the intubation.

Results: The degree of heart rate elevation was suppressed in the E1 and E2 groups compared to the C group, and RPP after intubation significantly decreased in the E2 group compared to the C group.

Conclusions: Esmolol injection, 1-2 mg/kg, prior to lightwand intubation effectively blunts heart rate elevation, and 2 mg/kg of esmolol injection blunts rate-pressure product elevation.

Keywords: Blood pressure; Esmolol; Heart rate; Intubation; Lightwand; Rate pressure product.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST No potential conflict of interest relevant to this article was reported.

Figures

Fig. 1.
Fig. 1.
Flowchart illustrating the selection of patients. C: control, E0.5: esmolol 0.5 mg/kg, E1: esmolol 1.0 mg/kg, E2: esmolol 2.0 mg/kg.
Fig. 2.
Fig. 2.
SBP changes with lightwand intubation in the four patient groups. All values are expressed as mean values. C: control, E0.5: esmolol 0.5 mg/kg, E1: esmolol 1.0 mg/kg, E2: esmolol 2.0 mg/kg, SBP: systolic blood pressure, TB: before induction (baseline), TI: 2 min before intubation (induction), T1: 1 min after intubation, T3: 3 min after intubation, T5: 5 min after intubation, T10: 10 min after intubation.
Fig. 3.
Fig. 3.
DBP changes with lightwand intubation in the four patient groups. All values are expressed as mean values. C: control, E0.5: esmolol 0.5 mg/kg, E1: esmolol 1.0 mg/kg, E2: esmolol 2.0 mg/kg, DBP: diastolic blood pressure, TB: before induction (baseline), TI: 2 min before intubation (induction), T1: 1 min after intubation, T3: 3 min after intubation, T5: 5 min after intubation, T10: 10 min after intubation.
Fig. 4.
Fig. 4.
MBP changes with lightwand intubation in the four patient groups. All values are expressed as mean values. C: control, E0.5: esmolol 0.5 mg/kg, E1: esmolol 1.0 mg/kg, E2: esmolol 2.0 mg/kg, MBP: mean blood pressure, TB: before induction (baseline), TI: 2 min before intubation (induction), T1: 1 min after intubation, T3: 3 min after intubation, T5: 5 min after intubation, T10: 10 min after intubation.
Fig. 5.
Fig. 5.
HR changes with lightwand intubation in the four patient groups. Comparison of measurements in C group and E1 group showed significant differences in HR at 1 min after intubation (T1) (100.11 vs. 85.34, P ≤ 0.001), as well as at 3 min after intubation (T3) (93.94 vs. 83.63, P = 0.02). Similarly, comparison of measurements in C group and E2 group demonstrated significant differences in HR at 1 min after intubation (T1) (100.11 vs. 87.09, P ≤ 0.001), as well as at 3 min after intubation (T3) (93.94 vs. 81.97, P ≤ 0.001). All values are expressed as mean values. C: control, E0.5: esmolol 0.5 mg/kg, E1: esmolol 1.0 mg/kg, E2: esmolol 2.0 mg/kg, HR: heart rate, TB: before induction (baseline), TI: 2 min before intubation (induction), T1: 1 min after intubation, T3: 3 min after intubation, T5: 5 min after intubation, T10: 10 min after intubation. *P < 0.05 compared with C group.
Fig. 6.
Fig. 6.
RPP changes with lightwand intubation in the four patient groups. Comparison of RPP measurements in C group and E2 group showed significant differences at 1 min after intubation (T1) (15,003.43 vs. 11,665.40, P = 0.001) and 3 min after intubation (T3) (12,162.37 vs. 9,861.89, P = 0.002). All values are expressed as mean values. C: control, E0.5: esmolol 0.5 mg/kg, E1: esmolol 1.0 mg/kg, E2: esmolol 2.0 mg/kg, RPP: rate-pressure product, TB: before induction (baseline), TI: 2 min before intubation (induction), T1: 1 min after intubation, T3: 3 min after intubation, T5: 5 min after intubation, T10: 10 min after intubation. *P < 0.05 compared with C group.

Similar articles

References

    1. Prys-Roberts C, Greene LT, Meloche R, Foëx P. Studies of anaesthesia in relation to hypertension. II. Haemodynamic consequences of induction and endotracheal intubation. Br J Anaesth. 1971;43:531–47. - PubMed
    1. Kanaide M, Fukusaki M, Tamura S, Takada M, Miyako M, Sumikawa K. Hemodynamic and catecholamine responses during tracheal intubation using a lightwand device (Trachlight) in elderly patients with hypertension. J Anesth. 2003;17:161–5. - PubMed
    1. Davis L, Cook-Sather SD, Schreiner MS. Lighted stylet tracheal intubation: a review. Anesth Analg. 2000;90:745–56. - PubMed
    1. Sintetos AL, Hulse J, Pritchett EL. Pharmacokinetics and pharmacodynamics of esmolol administered as an intravenous bolus. Clin Pharmacol Ther. 1987;41:112–7. - PubMed
    1. Wiest D. Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics. Clin Pharmacokinet. 1995;28:190–202. - PubMed

LinkOut - more resources